Skip to Content

The Risk of Hypothyroidism in Breast Cancer Patients Treated with Anti-oestrogens Tamoxifen and Letrozole

Anti-oestrogen tamoxifen, but not letrozole, is related to the risk of subclinical hypothyroidism and can influence the observed weight gain in breast cancer patients.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top